For the WD patients with typical clinical symptoms but only single or no heterozygous ATP7B mutation, it is plausible to hypothesize that the copper transporters (CTR1 and/or CTR2) might act as modifier genes to influence the WD phenotype. This evidence concerns the gene SLC31A2 and Wilson disease.